Provided by Tiger Trade Technology Pte. Ltd.

Commercial Metals

63.10
-0.1500-0.24%
Pre-market: 63.100.00000.00%07:36 EDT
Volume:785.79K
Turnover:49.70M
Market Cap:7.01B
PE:11.99
High:63.84
Open:62.46
Low:62.46
Close:63.25
52wk High:84.87
52wk Low:53.08
Shares:111.05M
Float Shares:109.72M
Volume Ratio:0.76
T/O Rate:0.72%
Dividend:0.74
Dividend Rate:1.17%
EPS(TTM):5.26
EPS(LYR):0.7400
ROE:13.79%
ROA:6.32%
PB:1.55
PE(LYR):85.27

Loading ...

U.S. RESEARCH ROUNDUP- Cisco, DTE Energy, Marvell Technology

Reuters
·
May 14

Commercial Metals upgraded to Buy from Neutral at UBS

TIPRANKS
·
May 14

Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates

GlobeNewswire
·
May 13

CoinMarketCap warns users over fake CMC token scam

cryptonews
·
May 13

CMC Corp Sees FY Net Y2.20B

Dow Jones
·
May 13

Fake 'CMC Tokens' Trigger Crypto Scam Alert From CoinMarketCap

utoday
·
May 13

Press Release: Neurogene Reports First Quarter 2026 Financial Results and Highlights Recent Updates

Dow Jones
·
May 13

Kyverna Therapeutics Announces Initiation of Rolling SPS BLA Submission and Reports First Quarter 2026 Financial Results

GlobeNewswire
·
May 13

Press Release: Unicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update

Dow Jones
·
May 12

Press Release: AN2 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business and Scientific Highlights

Dow Jones
·
May 12

Table: CMC Magnetics Apr Rev NT$601.8M Vs NT$611.1M

Dow Jones
·
May 11

CMC Corp Sees 1H Parent Pretax Y2.00B

Dow Jones
·
May 07

CMC Markets Executives Acquire Shares Under UK Incentive Plan

TIPRANKS
·
May 06

Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update

GlobeNewswire
·
May 06

Fate Therapeutics Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of FT819

GlobeNewswire
·
May 05

YD Bio Limited Reports Full Year 2025 Financial Results

GlobeNewswire
·
May 01

Alterity Therapeutics Releases Appendix 4C – Q3 FY26 Quarterly Cash Flow Report & Corporate Update

GlobeNewswire
·
Apr 30

Organogenesis Completes Rolling Submission of Biologics License Application for ReNu®

GlobeNewswire
·
Apr 29

Everton line up CMC Markets as shirt sponsor in £30m deal

cityam
·
Apr 28

Alterity Wins FDA Backing on CMC Plan for ATH434 Phase 3 in Multiple System Atrophy

TIPRANKS
·
Apr 27